Amphastar PharmaceuticalsAMPH +3.52%83 EV-to-FCF is 10.19 as of Jun. 28, 2026, which is 51% below its 10-year median of 20.61. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.79 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 562 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 77.05% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Amphastar Pharmaceuticals's Enterprise Value is $1,354.8 Mil.
Amphastar Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $132.9 Mil. Therefore, Amphastar Pharmaceuticals's EV-to-FCF for today is 10.19.
The historical rank and industry rank for Amphastar Pharmaceuticals's EV-to-FCF or its related term are showing as below:
AMPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -134.93 Med: 20.61 Max: 4909.4
Current: 10.19
During the past 13 years, the highest EV-to-FCF of Amphastar Pharmaceuticals was 4909.40. The lowest was -134.93. And the median was 20.61.
AMPH's EV-to-FCF is ranked better than 77.05% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs AMPH: 10.19
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amphastar Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Amphastar Pharmaceuticals's share price for today is $21.78.
Amphastar Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Amphastar Pharmaceuticals EV-to-FCF Related Terms
Amphastar Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's EV-to-FCF falls into.
Amphastar Pharmaceuticals's current Enterprise Value is $1,354.8 Mil.
Amphastar Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $132.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a EV-to-FCF of 10.19 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Amphastar Pharmaceuticals and its competitors. This is 51% below median its historical median of 20.61. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #129 out of 562 companies in the Drug Manufacturers industry, placing it in the top 23%.
Is Amphastar Pharmaceuticals' EV-to-FCF too high?
Amphastar Pharmaceuticals' current EV-to-FCF of 10.19 is 51% below median its 10-year median of 20.61. The Drug Manufacturers industry median EV-to-FCF is 20.11. Amphastar Pharmaceuticals' value of 10.19 is 49.3% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #129 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' EV-to-FCF compare to ETON and ESPR?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #129 out of 562 companies for EV-to-FCF. This places Amphastar Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.11. Amphastar Pharmaceuticals' value of 10.19 is 49.3% below this benchmark. While the company's 10-year median is 20.61 vs. the industry median of 20.11, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current EV-to-FCF of 10.19 is 49.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current EV-to-FCF is 10.19, which is 51% below median its own 10-year median of 20.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $21.78 — trading 55.4% below its estimated fair value. The current EV-to-FCF is 10.19, which is 51% below median its 10-year median of 20.61 and 49.3% below the Drug Manufacturers industry median of 20.11. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current EV-to-FCF is 10.19 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.78 is trading 55.4% below its estimated GF Value™ of $48.79.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
EV-to-FCF: 10.19 (51% below median its 10-year median of 20.61)
GF Value™: $48.79 vs. price of $21.78 (55.4% below fair value)
Industry Position: 49.3% below the Drug Manufacturers median (#129 of 562)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
